Drugs / hPAM4 IgG1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00364364 | May 2007 → Aug 2008 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hPAM4 IgG1 | “designated hPAM4 IgG1 in patients with known pancreatic cancer” NCT00364364 ↗ |
| Target | MUC1 | “indium-111 (111In)-labeled, humanized anti-MUC1 antibody” NCT00364364 ↗ |